<?xml version="1.0" encoding="UTF-8"?>
<p>The meta-analysis groups were: 1) liver protective drug plus antiviral drug versus antiviral drug alone to assess efficacy of altering ALT, AST, ALP and TBIL levels (
 <xref ref-type="table" rid="tbl28482">Table 1</xref>; 
 <xref ref-type="fig" rid="fig21153">Figure 1</xref>); 2) liver protective drug (treatment group) versus placebo to assess protective effects in terms of ALT and TBIL (
 <xref ref-type="table" rid="tbl28482">Table 1</xref>; 
 <xref ref-type="fig" rid="fig21157">figures 3</xref> and 
 <xref ref-type="fig" rid="fig21154">4</xref>); 3) combination of two hepatoprotective agents versus a single agent in terms of ALT, AST, ALP, GGT, TBIL (
 <xref ref-type="table" rid="tbl28482">Table 1</xref>; 
 <xref ref-type="fig" rid="fig21154">Figure 4</xref>); 4) one protective agent versus another in terms of normalization rates of ALT and TBIL (
 <xref ref-type="table" rid="tbl28482">Table 1</xref>; 
 <xref ref-type="fig" rid="fig21155">Figure 5</xref>); 5) evaluation of the effects of a combination of two kinds of protective agents versus a single protective agent in terms of HA, LN, IV-C and PIIIP (
 <xref ref-type="table" rid="tbl28482">Table 1</xref>; 
 <xref ref-type="fig" rid="fig21158">figures 6</xref> and 
 <xref ref-type="fig" rid="fig21159">7</xref>) as hepatic fibrosis markers.
</p>
